CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy

Inclusion Criteria: * Male or female; * 20-70 years old; * Ability to give informed consent; * Documented severe coronary heart disease, defined as at least 70% luminal diameter narrowing of at least three major coronary artery, suited to CABG; * Left ventricular dysfunction (LVEF) less than or equal to 35%, measured by MRI or less than or equal to 45%, measured by echocardiogram; * Presence of reversibility, as identified by single photon emission computed tomography (SPECT) isotope protocol; * At least 3 months since last episode of myocardial infarction; * Without a history of abdominal operation and severe abdominal diseases; * Negative pregnancy test (in women with childbearing potential. Exclusion Criteria: * Pregnant or lactating; * A history of malignancy in the last 5 years excluding basal cell carcinoma, that has been surgically removed, with proof of surgical clean margins; * a history of abdominal operation or severe abdominal diseases; * Positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Any condition requiring immunosuppressive medication; * Bleeding diathesis, defined as an international normalized ratio of at least 2.0 in the absence of warfarin therapy; * Hepatic dysfunction, as defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal range prior to study entry; * Chronic renal insufficiency, defined as a serum creatinine level greater than 2.5 mg/dL or requiring dialysis; * Leukocytes less than 4,000/µL or exceeding 10,000/µL; * Platelets less than 100,000/µL; * Hemoglobin less than 10 g/dL; * Chronic atrial fibrillation; * Less than 3 months since last episode of cerebral infarction; * Implantable cardioverter-defibrillator shock within 30 days of baseline consent, and within 30 days of randomization; * Presence of ventricular tachycardia lasting 30 seconds or more on 24-hour Holter monitor or electrocardiogram (ECG) performed during screening period; * Patients for whom it is impossible to perform both cardiac MRI; * Enrolled in an investigational device or drug study within the previous1 year; * Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.